Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Shared immune features correspond to high-risk multiple myeloma across multiple human subtypes and murine models

View Full Paper
Ask AI
Bookmark
Share

Authors

FNFnu NabuqiTMTarek H. MouhieddineKCKiana L. Chen

Discussion

Loading...

Member takes

Overview

Single-cell multi-omics reveals immune changes contributing to poor outcomes in multiple myeloma, indicating new therapeutic avenues.

Key Points

  • The study aims to define immune programs linked to high-risk multiple myeloma across human subtypes and mouse models.
  • Single-cell RNA sequencing of bone-marrow aspirates from 159 patients
  • Analysis of tumor micro-environment composition and clonal dynamics
  • Integrated ligand-receptor interaction profiling
  • In vivo modeling of high-risk versus standard risk myeloma using murine models
  • Identified distinct immune features linked to high-risk myeloma subtypes
  • Increased depletion of certain immune cells and expansion of activated T cells in high-risk tumors
  • High macrophage presence correlated with poor progression-free survival outcomes

Cite This Study

Nabuqi et al. (2025) studied this question.

synapsesocial.com/papers/69362f484fa91c937236d6d9https://doi.org/10.1182/blood-2025-5723
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Dissecting the multiple myeloma survival niche to improve novel treatment strategies2025
  2. 2An acquired immune-metabolic shift to common chemotherapy confers resistance to immunotherapies in relapsed, high-risk multiple myeloma2025
  3. 3How to approach the high-risk myeloma from induction through relapse?2025 · 1 citations
  4. 4Validation and refinement of the new high-risk multiple myeloma (HRMM) criteria in relapsed or refractory patients treated with BCMA CAR-T.2025
  5. 5Validation of the new ims/IMWG consensus genomic staging (CGS) of high-risk multiple myeloma (HRMM) in a contemporary cohort of 1209 patients2025 · 2 citations